KardiaMobile 6L can be used to measure QT duration in COVID-19 patients - Cardiac Rhythm News

KardiaMobile 6L, which it describes in a press release as the world’s only six lead personal ECG.

Using 12-Lead ECG to Detect Drug-Induced Long QT Interval: The Gold Standard

Artificial Intelligence–Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device

2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart

Implementation of a fully remote randomized clinical trial with cardiac monitoring

ECG tech cleared to monitor potential side-effects of COVID-19 treatments - Med-Tech Innovation

AliveCor gains US FDA clearance for KardiaMobile 6L to calculate patients' QTc interval - Medical Device News by Guided Solutions

Using 12-Lead ECG to Detect Drug-Induced Long QT Interval: The Gold Standard

Manual QT interval measurement with a smartphone-operated single-lead ECG versus 12-lead ECG: a within-patient diagnostic validation study in primary care

PDF) Feasibility of using KardiaMobile-L6 for QT interval monitoring during the early phase of the COVID-19 pandemic in critical care patients

Sensors, Free Full-Text

AliveCor gains US FDA clearance for KardiaMobile 6L to calculate patients' QTc interval - Medical Device News by Guided Solutions